Trial Profile

Phase 1/2 Study of VELCADE, Dexamethasone, and Revlimid Versus VELCADE, Dexamethasone, Cyclophosphamide, and Revlimid Versus VELCADE, Dexamethasone and Cyclophosphamide in Subjects With Previously Untreated Multiple Myeloma.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 14 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use
Acronyms EVOLUTION
Sponsors Millennium

17 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
22 Dec 2010 Planned end date changed from 1 Sep 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.
08 Dec 2009 Interim results presented at the 51st Annual Meeting and Exposition of the American Society of Hematology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com